osmolality has been known to increase ANP release. However, its physiological role in the regulation of atrial myocytic ANP release and the mechanism by which hyperosmolality increases ANP release are to be defined. The purpose of the present study was to define these questions. Experiments were performed in perfused beating rabbit atria. Hyperosmolality increased atrial ANP release, cAMP efflux, and atrial dynamics in a concentration-dependent manner. The osmolality threshold for the increase in ANP release was as low as 10 mosmol/ kgH2O (ϳ3%) above the basal levels (1.55 Ϯ 1. 71, 17.19 Ϯ 3.11, 23.15 Ϯ 5.49, 54.04 Ϯ 11.98, and 62.00 Ϯ 13.48% for 10, 20, 30, 60, and 100 mM mannitol, respectively; all P Ͻ 0.01). Blockade of sarcolemmal L-type Ca 2ϩ channel activity, which increased ANP release, attenuated hyperosmolality-induced increases in ANP release (Ϫ13.58 Ϯ 4.68% vs. 62.00 Ϯ 13.48%, P Ͻ 0.001) and cAMP efflux but not atrial dynamics. Blockade of the Ca 2ϩ release from the sarcoplasmic reticulum, which increased ANP release, attenuated hyperosmolality-induced increases in ANP release (13.44 Ϯ 7.47% vs. 62.00 Ϯ 13.48%, P Ͻ 0.01) and dynamics but not cAMP efflux. Blockades of Na ϩ -K ϩ -2Cl Ϫ cotransporter, Na ϩ /H ϩ exchanger, and Na ϩ /Ca 2ϩ exchanger had no effect on hyperosmolality-induced increase in ANP release. The present study suggests that hyperosmolality regulates atrial myocytic ANP release and that the mechanism by which hyperosmolality activates ANP release is closely related to the cross-talk between the sarcolemmal L-type Ca 2ϩ channel activity and sarcoplasmic reticulum Ca 2ϩ release, possibly inactivation of the L-type Ca 2ϩ channels.
atrial natriuretic peptide; L-type calcium channels; sarcoplasmic reticulum calcium release; hyperosmolality ACUTE INCREASE in osmolality increases ANP release in vitro and in vivo. Hyperosmolality accentuates ANP release in rat atrial block (4, 32) , atrial slice (48) , dispersed atrial myocytes (19) , and beating or nonbeating atria (40) . In humans, moderate or marked acute hyperglycemia increases plasma levels of ANP (5, 10, 31) . Some of these reports show that hyperosmolality by about 9 -13% of basal levels accentuates ANP release (4, 19) . Although the mechanism by which hyperglycemia increases plasma levels of ANP is difficult to differentiate from its effect induced by hypervolemia, these findings suggest that hyperosmolality may be a stimulant to increase atrial ANP release.
Hypertonicity by high extracellular osmolality results in a shrinkage of cardiomyocytes (14) . Hyperosmolality has been known to induce an activation of Na
Ϫ1 cotransporter (NKCC) in rabbit ventricular myocytes (14) (25) and [Ca 2ϩ ] i (3, 23, 25, 42) in cardiac ventricular myocytes.
The change in atrial volume has been considered the most important physiological factor in the regulation of ANP release (8, 13, 27) . There have also been reported various modulating factors for ANP release (35) . Ca 2ϩ has been known to have diverse effects on atrial ANP release, i.e., an increase or a decrease in ANP release. Many reports indicate that increase in Ca 2ϩ influx via L-type Ca 2ϩ channel activation increases ANP secretion in perfused hearts (36, 38) , isolated beating atria (39) , and contracting cultured atrial myocytes (30) . Similarly, sarcolemmal (SL) L-type Ca 2ϩ channel blocker inhibits ANP secretion in perfused hearts (38) , isolated beating atria (39) , and contracting atrial myocytes (30) . In contrast, some reports, including ours, indicate that Ca 2ϩ is negatively involved in the regulation of ANP release in perfused hearts (20, 37) and isolated beating atria (12, 47) .
The increase in plasma osmolality has been shown to elevate plasma levels of ANP in marine fishes (15, 45) . Especially, cardiac atrium has been shown to act as an osmoregulator secreting ANP in euryhaline eels (45) . The purpose of the present study was to answer the following questions. 1) What is the physiological role of hyperosmolality in the regulation of ANP release and threshold to detect changes in osmolality in beating rabbit atria? 2) What is the mechanism by which hyperosmolality activates atrial myocytic ANP release?
MATERIALS AND METHODS
Beating perfused atrial preparation. New Zealand White rabbits were used. An isolated perfused atrial preparation was prepared by the method described previously (7, 11) , which allowed atrial pacing and measurements of changes in atrial volume during contraction (stroke volume), pulse pressure, transmural extracellular fluid (ECF) translocation, cAMP efflux, and ANP secretion. Briefly, the hearts were removed and placed in oxygenated warm saline. The left atrium was then dissected. A calibrated transparent atrial cannula (8 cm long, 4 mm OD) containing two small catheters within it was inserted into the left atrium through the atrioventricular orifice. The cannula was secured by ligatures around the atrioventricular sulcus. The outer tip of the atrial cannula was open to allow for outflow from the atrium.
One of the two catheters located in the atrium was for inflow. The other catheter was used to record pressure changes in the atrium. The cannulated atrium was then transferred to an organ chamber containing buffer at 36.5°C. The pericardial space of the organ chamber was open to the air so as not to restrict atrial dynamics. The atrium was perfused with HEPES-buffered solution by means of a peristaltic pump (1 ml/min). The composition of the buffer was as follows (mM): 118 NaCl, 4.7 KCl, 2.5 CaCl 2, 1.2 MgCl2, 25 NaHCO3, 10.0 glucose, and 10.0 HEPES (with NaOH, pH 7.4) and 0.1% bovine serum albumin (osmolality, 300.4 Ϯ 2.6 mosmol/kgH 2O) (n ϭ 12). Soon after setup of the perfused atrium, transmural electrical field stimulation with a luminal electrode was started at 1.3 Hz (duration, 0.3 ms; voltage, 2 times threshold intensity, 20 -30 V; 6.1-cmH 2O distension). The perfusate was prewarmed to 36.5°C by passage through a water bath and equilibrated with oxygen by passage through silicone tubing in a gas mixing chamber. The buffer in the organ chamber was oxygenated by passing oxygen through silicone tubing coils located inside the chamber. Perfusate gas and pH were monitored via periodic sampling and measured with a pH/blood gas analyzer. The changes in atrial stroke volume were monitored by reading the lowest level of the water column in the calibrated atrial cannula during end diastole. Atrial pulse pressure was measured via a pressure transducer connected to the intra-atrial catheter and recorded on a physiograph. To estimate transendocardial ECF translocation, transmural atrial clearance of [ 3 H]inulin was measured. Radioactivity in the atrial perfusate and pericardial buffer solution was measured with a liquid scintillation system, and the amount of ECF translocated through the atrial wall was calculated as follows: ECF translocated (l⅐min Ϫ1 ⅐g atrial wt
Ϫ1
) ϭ [total radioactivity in the perfusate (cpm/min) ϫ 1,000]/[radioactivity in the pericardial reservoir (cpm/l) ϫ atrial wet wt (mg)].
Experimental protocols. The atria were perfused for 60 min to stabilize ANP secretion. The atria were paced at 1.3 Hz. [ 3 H]inulin was introduced to the pericardial fluid 20 min before the start of the sample collection (7). The perfusate was collected at 2-min intervals at 4°C for analyses. Experiments were carried out by using six groups of atria to define the concentration-dependent effects of mannitol (Fig.  1 ). Control cycles (four 12-min periods) were followed by mannitol (6 mM, group 1, n ϭ 3; 10 mM, group 2, n ϭ 9; 20 mM, group 3, n ϭ 9; 30 mM, group 4, n ϭ 6; 60 mM, group 5, n ϭ 5; 100 mM, group 6, n ϭ 8; vehicle, group 26, n ϭ 9). To define the role of SL L-type Ca 2ϩ channel activity in the hyperosmolality-induced responses, three cycles (36 min) of nifedipine (1 M), an L-type Ca 2ϩ channelselective inhibitor, were followed by an administration of mannitol (100 mM) or vehicle for three cycles in the presence of nifedipine (group 8, n ϭ 10; nifedipine alone, group 9, n ϭ 10). Three cycles of mannitol (100 mM) were also followed by nifedipine or vehicle for three cycles in the presence of mannitol (group 10, n ϭ 6; mannitol alone, group 11, n ϭ 6). To define the role of the Ca 2ϩ release from the sarcoplasmic reticulum (SR) in the hyperosmolality-induced responses, three cycles of combined infusion of ryanodine ( , ion channels, and protein kinases were in the range of doses used previously (11, 18, 28, 29, 33, 34, 46) .
Radioimmunoassay of ANP.
Immunoreactive ANP in the perfusate was measured by a specific radioimmunoassay as described previously (7). The secreted amount of immunoreactive ANP was expressed as nanograms of ANP per minute per gram of atrial tissue. The molar concentration of immunoreactive ANP in terms of the ECF translocation reflects the concentration of ANP in the interstitial space of the atrium and, therefore, indicates the rate of myocytic release of ANP into the surrounding paracellular space (7). It was calculated as
Most of the ANP secreted is processed ANP (7) .
Radioimmunoassay of cAMP. cAMP was measured by equilibrated radioimmunoassay as described previously (11) . Briefly, standards and samples were taken up in a final volume of 100 l of 50 mM sodium acetate buffer (pH 4.8) containing theophylline (8 mM), and then 100 l of diluted cAMP antiserum (Calbiochem-Novabiochem, San Diego, CA) and iodinated 2Ј-O-monosuccinyl-adenosine 3Ј,5Ј-cyclic monophosphate tyrosyl methyl ester were added and incubated for 24 h at 4°C. For the acetylation reaction, 5 l of a mixture of acetic anhydride and triethylamine was added to the assay tube before the addition of antiserum and tracer. The amount of cAMP efflux was expressed as picomoles cAMP per minute per gram atrial tissue. The molar concentration of cAMP efflux in terms of the ECF translocation reflects the concentration of cAMP in the interstitial space of the atrium. It was calculated as cAMP efflux concentration
For the preparation of perfusates, 100 l of the perfusate were treated with trichloroacetic acid for a final concentration of 6% for 15 min at room temperature and were centrifuged at 4°C. The supernatant was transferred to a polypropylene tube, extracted with water-saturated ether, and then dried by using a SpeedVac concentrator (Savant, Farmingdale, NY). The dried samples were resuspended with sodium acetate buffer.
Statistical analysis. Significant difference was compared by using repeated-measures ANOVA followed by Bonferroni's multiple-comparison test (see Figs. 2, 4, 5, and 7). Student's t-test for unpaired data (see Figs. 3, 6, 8, and 9 ) was also applied. Statistical significance was defined as P Ͻ 0.05. The results are given as means Ϯ SE.
RESULTS
Hyperosmolality activates atrial myocytic ANP release in a concentration-dependent manner. ANP secretion, ECF translocation, and the concentration of ANP in terms of the ECF translocation, which reflects the rate of atrial myocytic ANP release, were stable during the control periods (Fig. 2 , Aa-Ac and Ba-Bc). cAMP efflux, the concentration of cAMP in perfusate in terms of the ECF translocation and atrial dynamics, atrial stroke volume, and pulse pressure were also steady and stable (Fig. 2 , Ad-Ag and Bd-Bg). Hyperosmotic solution (30 mM mannitol added to regular HEPES buffer) increased ANP secretion, the concentration of ANP, cAMP efflux, and atrial stroke volume and pulse pressure ( Fig. 2A) . Hyperosmolality-induced increases in ANP concentration and cAMP efflux concentration continuously progressed. Hyperosmolalityinduced increase in atrial dynamics showed a peak and waned.
Hyperosmolality-induced increase in ANP release was significant at a concentration as low as ϳ10 mosmol/kgH 2 O above the basal level (315.8 Ϯ 0.7 mosmol/kgH 2 O, n ϭ 8, 10 mM mannitol added vs. 304.4 Ϯ 1.4 mosmol/kgH 2 O, n ϭ 8, regular buffer). Hyperosmolality (10 mosmol/kgH 2 O) significantly increased ANP concentration at the third cycle of infusion (1.55 Ϯ 1.71%, n ϭ 9, for hyperosmolality vs. Ϫ6.13 Ϯ 1.76%, n ϭ 9, for time-matched control; P Ͻ 0.05; Fig. 3 ). Hyperosmolality (10 mM) significantly increased cAMP efflux concentration at the third cycle of infusion (38.21 Ϯ 11.43%, n ϭ 7, for hyperosmolality vs. 3.43 Ϯ 3.88%, n ϭ 9, for time-matched control; P Ͻ 0.01). Hyperosmolality (10 mM)-induced increase in atrial dynamics was not significant. As shown in Fig. 3 , hyperosmolality increased atrial myocytic ANP release, atrial stroke volume and pulse pressure, and cAMP efflux in a concentration-dependent manner. Hyperosmotic solution containing glucose increased ANP release with equal potency (17.85 Ϯ 2.36%, n ϭ 3, and 55.63 Ϯ 10 18%, n ϭ 4, for 30 and 60 mM, respectively). No. of experiments: 6 mM mannitol, n ϭ 3; 10 mM mannitol, n ϭ 9; 20 mM mannitol, n ϭ 9; 30 mM mannitol, n ϭ 6; 60 mM mannitol, n ϭ 5; 100 mM mannitol, n ϭ 8; control, n ϭ 9. Data for mannitol (30 and 100 mM) and control were derived from Figs. 2 and 7A. Values are means Ϯ SE. *P Ͻ 0.05, ϩ P Ͻ 0.01 vs. control.
L-type Ca
2ϩ channel inhibition with nifedipine blocks hyperosmolality-induced activation of atrial myocytic ANP release. To define the mechanism by which hyperosmolality activates atrial myocytic ANP release, the role of the SL L-type Ca 2ϩ channels was tested. Blockade of L-type Ca 2ϩ channel activity with nifedipine increased ANP secretion and atrial myocytic ANP release concomitantly with a decrease in atrial stroke volume and pulse pressure (see Figs. 4, A and B, and 6A , middle column). Nifedipine had no effect on cAMP efflux (see Figs. 4, Ab and Bb, and 6A, middle column). The effects of nifedipine maintained after the third cycle of infusion. These results indicate that Ca 2ϩ entry via L-type channel activation decreases atrial myocytic ANP release. In the presence of nifedipine, hyperosmolality (100 mM mannitol added) failed to activate myocytic ANP release (ANP concentration 62.00 Ϯ 13.48%, n ϭ 8, for mannitol vs. Ϫ6.13 Ϯ 1.76%, n ϭ 9, for time-matched control, P Ͻ 0.001; Ϫ13.58 Ϯ 4.68%, n ϭ 10, for nifedipine plus mannitol vs. Ϫ12.02 Ϯ 5.28%, n ϭ 10, for nifedipine alone, P Ͼ 0.05; see Figs. 4Ba, 6B, middle, and 7Aa). Nifedipine failed to block hyperosmolality-induced increase in atrial dynamics (for atrial stroke volume: 13.31 Ϯ 4.57%, n ϭ 8, for mannitol vs. Ϫ2.04 Ϯ 1.21%, n ϭ 9, for time-matched control, P Ͻ 0.01; 200.99 Ϯ 56.57%, n ϭ 10, for nifedipine plus mannitol vs. Ϫ42.62 Ϯ 6.31%, n ϭ 10, for nifedipine alone, P Ͻ 0.001; for atrial pulse pressure: 11.49 Ϯ 1.59%, n ϭ 8, for mannitol vs. Ϫ1.73 Ϯ 1.23%, n ϭ 9, for control, P Ͻ 0.001; 48.01 Ϯ 9.29%, n ϭ 10, for nifedipine plus mannitol vs. Ϫ21.46 Ϯ 3.27%, n ϭ 10, for nifedipine alone, P Ͻ 0.001; see Figs. 4, Bc and Bd, and 6B, middle column). Hyperosmolality-induced increase in cAMP efflux concentration was not observed in the presence of nifedipine (65.78 Ϯ 15.84%, n ϭ 8, for mannitol vs. 3.43 Ϯ 3.88%, n ϭ 9, for time-matched control, P Ͻ 0.01; 30.34 Ϯ 8.60%, n ϭ 10, for nifedipine plus mannitol vs. 17.76 Ϯ 6.11%, n ϭ 10, for nifedipine alone, P Ͼ 0.05; see Figs. 4Bb and 6B, middle column). These results indicate that hyperosmolality-induced activation of atrial myocytic ANP release is closely related to the L-type Ca 2ϩ channel activity (Fig. 4C) . To further define the effects of mannitol, the effects of nifedipine were tested in the presence of mannitol. Hyperosmolality (100 mM mannitol added) increased atrial myocytic ANP release (Figs. 5Aa and 6A, right column) . Hyperosmolality-induced increase in ANP release showed a peak and waned (Figs. 5Aa and 6B, right column) . Hyperosmolality induced increases in atrial stroke volume and pulse pressure, and cAMP efflux was maintained (Figs. 5, Ab-Ad, and 6A, right column). In the presence of hyperosmolality, nifedipine failed to activate atrial ANP release (Figs. 5Ba and 6B, right column). In the presence of hyperosmolality, nifedipine decreased atrial stroke volume and pulse pressure without changes in hyperosmolality-induced increase in cAMP efflux (Figs. 5, Bb-Bd, and 6B, right column). These results indicate that hyperosmolality interferes with nifedipine-induced increase in ANP release (Fig. 5C) .
Inhibition of SR Ca 2ϩ release with ryanodine plus thapsigargin attenuates hyperosmolality-induced activation of atrial myocytic ANP release.
Because cross-talk between the SL L-type Ca 2ϩ channels and SR Ca 2ϩ release has a fundamental importance in the regulation of cardiac [Ca 2ϩ ] i homeostasis, the role of the SR function in the hyperosmolality-induced activation of atrial ANP release was tested. Blockade of the SR Ca 2ϩ release by combined treatment with ryanodine and thapsigargin slightly but not significantly increased atrial ANP release concomitantly with a decrease in atrial stroke volume and pulse pressure (Fig. 7, B and C) . The results indicate that the SR Ca 2ϩ release is negatively involved in the regulation of ANP release. In the blockade of the SR Ca 2ϩ release, hyperosmolality failed to increase atrial myocytic ANP release and atrial stroke volume and pulse pressure (Figs. 7 , Ba, Bc, and Bd, and 8). In the blockade of the SR Ca 2ϩ release, hyperosmolality increased cAMP efflux (Figs. 7Bb and 8) . Effects of thapsigargin plus ryanodine were stable during the corresponding periods (Figs. 7C and 8) . These results indicate that hyperosmolality-induced increase in ANP release is closely related to the SR Ca 2ϩ release. Inhibition of NKCC, NHX, and NCX has no effect on hyperosmolality-induced activation of atrial myocytic ANP release. Because hyperosmolality has been shown to activate NKCC (14) , NHX (17) and possibly NCX in the heart (25), the role of these functions in the hyperosmolality-induced increase in ANP concentration (release) was tested (Fig. 9) . Blockade of NKCC with bumetanide decreased ANP release by 16.39 Ϯ 3.50% up to the third cycle of infusion. Bumetanide failed to block the hyperosmolality-induced increases in atrial ANP release and stroke volume. Blockade of NHX with EIPA decreased ANP release by 34.63 Ϯ 4.6% up to the third cycle.
EIPA failed to block hyperosmolality-induced increases in ANP release and stroke volume. Blockade of reverse mode of the NCX with KB-R decreased atrial ANP release by 38.42 Ϯ 5.38% up to third cycle. KB-R failed to modify the hyperosmolality-induced increases in ANP release and stroke volume. Similarly, blockade of NCX with DCB failed to block hyperosmolality-induced increases in atrial ANP release and stroke volume. Neither bumetanide nor DCB alone showed significant changes in ANP release during the period corresponding to mannitol infusion compared with time-matched control. EIPA (Ϫ34.60 Ϯ 8.86%, n ϭ 3, vs. Ϫ6.13 Ϯ 1.76%, n ϭ 9, P Ͻ 0.001) and KB-R (Ϫ37.41 Ϯ 6.23%, n ϭ 5, vs. Ϫ6.13 Ϯ 1.76%, n ϭ 9, P Ͻ 0.001) alone decreased ANP release during the corresponding period. Protein kinase inhibition with SB or staurosporine has no effect on hyperosmolality-induced activation of atrial myocytic ANP release. It was shown that hyperosmolality activates p38 MAP kinase signaling pathways (2) . To define the role of p38 MAP kinase in the hyperosmolality-induced increase in ANP release, the effect of SB was tested (Fig. 9) . Blockade of p38 MAP kinase with SB decreased ANP release by 39.44 Ϯ 3.43% up to third cycle. SB had no significant effect on the hyperosmolality-induced increase in ANP release. Staurosporine decreased ANP release by 13.44 Ϯ 3.43% up to the third cycle. Staurosporine had no effect on the hyperosmolalityinduced increase in ANP release (Fig. 9) . SB but not staurosporine alone decreased ANP release during the period corresponding to mannitol infusion compared with time-matched control (Ϫ28.87 Ϯ 10.09%, n ϭ 3, vs. Ϫ6.13 Ϯ 1.76%, n ϭ 9, P Ͻ 0.01).
DISCUSSION
The present study explores the role of hyperosmolality on the regulation of atrial myocytic ANP release.
Osmoregulation of atrial myocytic ANP release. The present study indicates that an increase in extracellular osmolality is a powerful stimulant to induce an increase in atrial myocytic ANP release, cAMP production, and atrial dynamics. Hyperosmotic stimulation with mannitol or glucose increased ANP release with equal potency. The responses were concentration dependent up to 100 mosmol/kgH 2 O above the basal levels of osmolality. The responses to the changes in osmolality were fairly sensitive to detect it at levels as low as 3% above basal levels. Mannitol (10 mM) significantly increased atrial ANP release. These results indicate that the cardiac atrium is sensitive to detect changes in fluid osmolality and to respond by increasing atrial myocytic ANP release. This suggests that the changes in fluid osmolality as well as volume could be one of the physiological stimulants in the regulation of atrial myocytic ANP release. Therefore, it is possible to hypothesize that the cardiac atrium has a role in the regulation of body fluid osmolality as well as fluid volume and hydrostatic pressure balance as an osmoregulator.
The heart is involved in the osmoregulation in marine fishes (15, 45) . However, in mammals it was not tested that the changes in fluid osmolality could be a regulator to control the ANP release in the physiological ranges. Hyperosmolality (9 -12.9% above the basal osmolality) has been shown to activate atrial ANP release (4, 19) . The response was also observed by a much higher increase in osmolality in rat atrial block (32, 48) and atria (40) .
Both the L-type Ca 2ϩ channels and SR Ca 2ϩ release are involved in the hyperosmolality-induced increase in atrial myocytic ANP release. Ca 2ϩ entry via SL L-type Ca 2ϩ channel activation decreases atrial myocytic ANP release (22, 47) . It was shown that SR Ca 2ϩ release was positively (9, 21, 24, 26, 30, 39) or negatively (29) channels in the regulation of atrial ANP release has yet to be defined. L-type Ca 2ϩ channel blockade attenuated hyperosmolalityinduced increase in atrial myocytic ANP release. Previously, it was shown that L-type Ca 2ϩ channel activation with Bay K 8644 decreased and inhibition with inhibitors increased atrial ANP release in beating rabbit atria (47) . This means that the Ca 2ϩ entry via L-type Ca 2ϩ channels inhibits atrial myocytic ANP release. Taken together with the present data, hyperosmolality-induced increase in ANP release is related with the L-type Ca 2ϩ channel activity but not with the Ca 2ϩ entry per se (Fig. 10) . Therefore, it is possible to postulate that inactivation of the channels is involved in the hypertonicity-induced release attenuated hyperosmolality-induced increase in atrial ANP release. This suggests that the Ca 2ϩ release from the SR is related to the hyperosmolality-induced increase in ANP release. However, Ca 2ϩ release from the SR per se decreases atrial ANP release in the present and our previous data (29) .
Hyperosmolality-induced activation of ANP release may be related to the changes in the [Ca 2ϩ ] i in the Ca 2ϩ microdomain (1, 41) (Fig. 10) . It was shown in the skeletal muscle that hypertonicity decreased the tiny gap between the SL and subsarcolemmal SR (6) . From this notion, it is possible to hypothesize that enhanced inactivation of L-type Ca 2ϩ channels is related to the hyperosmolality-induced increase in ANP release (Fig. 10) .
The hyperosmolality-induced increase in ANP release was accompanied by increases in atrial dynamics and cAMP production. The changes in cAMP production and atrial dynamics were closely related to the function of the L-type Ca 2ϩ channel activity and SR Ca 2ϩ release, respectively. Blockade of the SR function attenuated hyperosmolality-induced increase in atrial dynamics but not cAMP production. Also, blockade of L-type Ca 2ϩ channels attenuated increase in cAMP production but not atrial dynamics. Hyperosmolality-induced increase in atrial dynamics may be related to the accentuation of the SR Ca 2ϩ release (Fig. 10) .
The present data indicate that the change in cAMP production is not directly related to the hypertonicity-induced increase in ANP release. This contrasts the previous reports showing that histamine-or forskolin-induced decrease in ANP release is related to the increase in cAMP production (11, 28) . This finding suggests that cAMP is compartmentalized in the regulation of hyperosmolality-induced ANP release. The present data also show that hyperosmolality-induced increase in atrial dynamics is not related to an activation of ANP release.
NKCC, NHX, NCX, and some protein kinases are not involved in the hyperosmolality-induced increase in atrial ANP release. NKCC blockade had no significant effects on the hyperosmolality-induced increases in ANP release and atrial dynamics. Similarly, blockades of NHX and NCX had no significant effect on the hyperosmolality-induced increase in ANP release. Previously, it was shown that the SL Ca 2ϩ entry involved in the Ca 2ϩ release from the SR by CICR was mainly L-type Ca 2ϩ channels (1, 41) . The present finding that Na ϩ or Ca 2ϩ entry via NKCC, NHX, or NCX is not involved in the hyperosmolality-induced increase in ANP release is relevant to this notion. Previously, Schiebinger et al. (40) reported that NCX is involved in the hyperosmolality-induced increase in ANP release. The present study contrasts to the report.
The present finding suggests that staurosporine-sensitive protein kinase(s) or p38 MAP kinase is not involved in the hyperosmolality-induced increase in ANP release.
It is possible that neurotransmitters released from nerve endings (35, 43) may be involved in the hyperosmolalityinduced increase in ANP release. However, it may not be the case. In our experimental model, an activation of adrenoceptors decreased ANP release. Also, acetylcholine showed a transient but little ANP effect with a decrease in atrial dynamics (unpublished data).
In summary, cardiac atrium has a role for the regulation of osmolality as well as volume of the body fluid via ANP release. The present study suggests that the cross-talk between the SL L-type Ca 2ϩ channels and SR Ca 2ϩ release, possibly inactivation of the L-type Ca 2ϩ channels, is involved in the osmotransduction to activate ANP release. release may also be related to the hyperosmolality-induced increase in atrial dynamics. RyR, ryanodine receptor; SERCA, sarcoplasmic reticulum Ca 2ϩ -ATPase; ϩ, activation; Ϫ, inhibition.
